---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-024920"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:09:52.485998+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M

## Summary
- Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.
- Has 45 days (until July 5, 2024) to submit a compliance plan to Nasdaq Staff.
- If plan accepted, Staff may grant up to 180-day extension to regain compliance.
- No immediate effect on listing; common stock continues trading on Nasdaq under AVTX.
- Company evaluating options; no assurance of regaining compliance or avoiding delisting.

## SEC filing metadata
- accession: 0001628280-24-024920
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024024920/0001628280-24-024920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024024920/avtx-20240520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-024920
- JSON: https://secwatch.observer/filing/0001628280-24-024920.json
- Plain text: https://secwatch.observer/filing/0001628280-24-024920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.